New oral cocktail aims to tame myeloma with fewer side effects
NCT ID NCT02412228
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 28 times
Summary
This phase 2 study tested a combination of three oral drugs (ixazomib, cyclophosphamide, and dexamethasone) as the first treatment for multiple myeloma in 12 newly diagnosed patients. The goal was to see if this all-oral regimen could control the disease effectively while causing less nerve damage than older treatments. The study measured how many patients responded and what side effects occurred.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Hospital of Rhode Island
Pawtucket, Rhode Island, 02860, United States
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
The Miriam Hospital
Providence, Rhode Island, 02906, United States
Conditions
Explore the condition pages connected to this study.